Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

EBV attachment stimulates FHOS/FHOD1 redistribution and co-aggregation with CD21: formin interactions with the cytoplasmic domain of human CD21.

Gill MB, Roecklein-Canfield J, Sage DR, Zambela-Soediono M, Longtine N, Uknis M, Fingeroth JD.

J Cell Sci. 2004 Jun 1;117(Pt 13):2709-20. Epub 2004 May 11.

3.

The Epstein-Barr virus-binding site on CD21 is involved in CD23 binding and interleukin-4-induced IgE and IgG4 production by human B cells.

Henchoz-Lecoanet S, Jeannin P, Aubry JP, Graber P, Bradshaw CG, Pochon S, Bonnefoy JY.

Immunology. 1996 May;88(1):35-9.

4.

Activation of the Rac-binding partner FHOD1 induces actin stress fibers via a ROCK-dependent mechanism.

Gasteier JE, Madrid R, Krautkrämer E, Schröder S, Muranyi W, Benichou S, Fackler OT.

J Biol Chem. 2003 Oct 3;278(40):38902-12. Epub 2003 Jul 10.

5.

Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein-Barr virus receptor, CR2) that binds iC3b and CD23.

Frémeaux-Bacchi V, Bernard I, Maillet F, Mani JC, Fontaine M, Bonnefoy JY, Kazatchkine MD, Fischer E.

Eur J Immunol. 1996 Jul;26(7):1497-503.

PMID:
8766552
6.

Defining in vivo transcription factor complexes of the murine CD21 and CD23 genes.

Debnath I, Roundy KM, Weis JJ, Weis JH.

J Immunol. 2007 Jun 1;178(11):7139-50.

7.

Binding of the intracellular Fas ligand (FasL) domain to the adaptor protein PSTPIP results in a cytoplasmic localization of FasL.

Baum W, Kirkin V, Fernández SB, Pick R, Lettau M, Janssen O, Zörnig M.

J Biol Chem. 2005 Dec 2;280(48):40012-24. Epub 2005 Oct 4.

8.
9.

Modulation of murine complement receptor type 2 (CR2/CD21) ectodomain shedding by its cytoplasmic domain.

Hoefer MM, Aichem A, Knight AM, Illges H.

Mol Immunol. 2008 Apr;45(8):2127-37. doi: 10.1016/j.molimm.2007.12.015. Epub 2008 Mar 4.

PMID:
18295335
10.

Identification of FHOD1-binding proteins and mechanisms of FHOD1-regulated actin dynamics.

Westendorf JJ, Koka S.

J Cell Biochem. 2004 May 1;92(1):29-41.

PMID:
15095401
11.
12.

Analysis of host gene expression changes reveals distinct roles for the cytoplasmic domain of the Epstein-Barr virus receptor/CD21 in B-cell maturation, activation, and initiation of virus infection.

Arredouani MS, Bhasin MK, Sage DR, Dunn LK, Gill MB, Agnani D, Libermann TA, Fingeroth JD.

J Virol. 2014 May;88(10):5559-77. doi: 10.1128/JVI.03099-13. Epub 2014 Mar 5.

13.

The Formin family protein, formin homolog overexpressed in spleen, interacts with the insulin-responsive aminopeptidase and profilin IIa.

Tojo H, Kaieda I, Hattori H, Katayama N, Yoshimura K, Kakimoto S, Fujisawa Y, Presman E, Brooks CC, Pilch PF.

Mol Endocrinol. 2003 Jul;17(7):1216-29. Epub 2003 Apr 3.

PMID:
12677009
14.

Internalization and molecular interactions of human CD21 receptor.

Tessier J, Cuvillier A, Glaudet F, Khamlichi AA.

Mol Immunol. 2007 Mar;44(9):2415-25. Epub 2006 Nov 21.

PMID:
17118449
15.

Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21).

Young KA, Chen XS, Holers VM, Hannan JP.

J Biol Chem. 2007 Dec 14;282(50):36614-25. Epub 2007 Oct 9.

16.
17.

Oligomerization of the diaphanous-related formin FHOD1 requires a coiled-coil motif critical for its cytoskeletal and transcriptional activities.

Madrid R, Gasteier JE, Bouchet J, Schröder S, Geyer M, Benichou S, Fackler OT.

FEBS Lett. 2005 Jan 17;579(2):441-8.

18.

Epstein-Barr virus encoded nuclear protein EBNA-3 binds XAP-2, a protein associated with Hepatitis B virus X antigen.

Kashuba E, Kashuba V, Pokrovskaja K, Klein G, Szekely L.

Oncogene. 2000 Mar 30;19(14):1801-6.

19.

Characterization of a 70-kDa, EBV gp350/220-binding protein on HSB-2 T cells.

Hedrick JA, Lao Z, Lipps SG, Wang Y, Todd SC, Lambris JD, Tsoukas CD.

J Immunol. 1994 Nov 15;153(10):4418-26.

PMID:
7963519
20.

Analysis of Epstein-Barr virus (EBV) receptor CD21 on peripheral B lymphocytes of long-term EBV- adults.

Jabs WJ, Paulsen M, Wagner HJ, Kirchner H, Klüter H.

Clin Exp Immunol. 1999 Jun;116(3):468-73.

Supplemental Content

Support Center